Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer
Crossref DOI link: https://0-doi-org.brum.beds.ac.uk/10.1186/s13045-017-0400-8
Published Online: 2017-01-23
Published Print: 2017-12
Update policy: https://0-doi-org.brum.beds.ac.uk/10.1007/springer_crossmark_policy
Zhang, Xiaoxue
Liu, Dan
Li, Mengchen
Cao, Canhui
Wan, Dongyi
Xi, Bixin
Li, Wenqian
Tan, Jiahong
Wang, Ji
Wu, Zhongcai
Ma, Ding
Gao, Qinglei
Funding for this research was provided by:
National Natural Science Foundation of China (81572570, 81502250, 81372801, 81472783, 81230038)